My Cart [ 0 ]
Home > Antibodies > Isotype Control Antibodies > Human IgG1 Isotype Control Antibody

Human IgG1 Isotype Control Antibody

hIgG1 Isotype Control, hIgG1 D265A N297A, IgG1 LALAPG, IgG1 SELF Mutants

Catalog No. Product Name Size List Price (US$) Quantity
PA007125 In Vivo Grade Recombinant Human IgG1 Isotype Control Antibody 1 mg 150.00
PA007125 In Vivo Grade Recombinant Human IgG1 Isotype Control Antibody 5 mg 300.00
PA007125 In Vivo Grade Recombinant Human IgG1 Isotype Control Antibody 25 mg 800.00
PA007125.05 In Vivo Grade Recombinant Human IgG1 Isotype Control Antibody, Endotoxin 0.05 EU/mg 5 mg 450.00
PA007125.05 In Vivo Grade Recombinant Human IgG1 Isotype Control Antibody, Endotoxin 0.05 EU/mg 25 mg 1200.00
PA007134 In Vivo Grade Recombinant Human IgG1-L234A L235A P329G (LALAPG) Isotype Control Antibody 1 mg 150.00
PA007134 In Vivo Grade Recombinant Human IgG1-L234A L235A P329G (LALAPG) Isotype Control Antibody 5 mg 300.00
PA007134 In Vivo Grade Recombinant Human IgG1-L234A L235A P329G (LALAPG) Isotype Control Antibody 25 mg 800.00
PA007134.05 In Vivo Grade Recombinant Human IgG1-L234A L235A P329G (LALAPG) Isotype Control Antibody, Endotoxin 0.05 EU/mg 5 mg 450.00
PA007134.05 In Vivo Grade Recombinant Human IgG1-L234A L235A P329G (LALAPG) Isotype Control Antibody, Endotoxin 0.05 EU/mg 25 mg 1200.00
PA007133 In Vivo Grade Recombinant Human IgG1-N297A Isotype Control Antibody 1 mg 150.00
PA007133 In Vivo Grade Recombinant Human IgG1-N297A Isotype Control Antibody 5 mg 300.00
PA007133 In Vivo Grade Recombinant Human IgG1-N297A Isotype Control Antibody 25 mg 800.00
PA007133.05 In Vivo Grade Recombinant Human IgG1-N297A Isotype Control Antibody, Endotoxin 0.05 EU/mg 5 mg 450.00
PA007133.05 In Vivo Grade Recombinant Human IgG1-N297A Isotype Control Antibody, Endotoxin 0.05 EU/mg 25 mg 1200.00
PA007132 In Vivo Grade Recombinant Human IgG1-D265A Isotype Control Antibody 1 mg 150.00
PA007132 In Vivo Grade Recombinant Human IgG1-D265A Isotype Control Antibody 5 mg 300.00
PA007132 In Vivo Grade Recombinant Human IgG1-D265A Isotype Control Antibody 25 mg 800.00
PA007139 In Vivo Grade Recombinant Human IgG1-D265A N297A Isotype Control Antibody 1 mg 150.00
PA007139 In Vivo Grade Recombinant Human IgG1-D265A N297A Isotype Control Antibody 5 mg 300.00
PA007139 In Vivo Grade Recombinant Human IgG1-D265A N297A Isotype Control Antibody 25 mg 800.00
PA007140 In Vivo Grade Recombinant Human IgG1-S267E L328F (SELF) Isotype Control Antibody 1 mg 150.00
PA007140 In Vivo Grade Recombinant Human IgG1-S267E L328F (SELF) Isotype Control Antibody 5 mg 300.00
PA007140 In Vivo Grade Recombinant Human IgG1-S267E L328F (SELF) Isotype Control Antibody 25 mg 800.00
PA006829 In Vivo Grade Recombinant Human IgG1-I253A H310A H435A (IAHAHA) Isotype Control Antibody 1 mg 150.00
PA006829 In Vivo Grade Recombinant Human IgG1-I253A H310A H435A (IAHAHA) Isotype Control Antibody 5 mg 300.00
PA006829 In Vivo Grade Recombinant Human IgG1-I253A H310A H435A (IAHAHA) Isotype Control Antibody 25 mg 800.00
PA006830 In Vivo Grade Recombinant Human IgG1-M252Y S254T T256E (YTE) Isotype Control Antibody 1 mg 150.00
PA006830 In Vivo Grade Recombinant Human IgG1-M252Y S254T T256E (YTE) Isotype Control Antibody 5 mg 300.00
PA006830 In Vivo Grade Recombinant Human IgG1-M252Y S254T T256E (YTE) Isotype Control Antibody 25 mg 800.00
Description

Background of Recombinant Human IgG1 Isotype Control Antibody

Different from polyclonal "human IgG1 isotype control antibodies" purified from human myeloma serum, the recombinant human IgG1 isotype control (hIgG1 kappa isotype control antibody) and mutants are produced in mammalian cells (HEK293 and CHO cells), thus are monoclonal and there is no potential contamination of any other antibody isotype(s). The recombinant human IgG1 isotype control has low or no specific binding to any human sample, and humanized or completely human variable regions in addition to the human IgG1 kappa constant regions. The human IgG1 kappa isotype control and mutants such as Fc-silenced can be used in ELISA, Western blot (WB), the cell-based assay or animal model as the antibody negative control.

A number of hIgG1 isotype control mutants are available. Most of the therapeutic antibody drugs carry the natural human IgG1 constant regions. There are some engineered mutants in the IgG1 Fc fragment. Changes to the IgG Fc sequence including glycosylation sites (such as N297A or N297G) have been used to modulate Fc functions. Even a single mutation may have both enhancement and abrogation effects on Fc binding though multiple mutation combinations are commonly used. We generated hIgG1 isotype control mutants, the same mutations as those in the therapeutic antibodies and candidates because such human IgG1 isotype control mutants are needed when clients test their engineered antibody candidates. For example, P329G substitution combined with L234A L235A (hIgG1 LALAPG, Fc silenced) was shown to decrease effector functions by disrupting the Fc/Fcγ receptor interface. The silent Fc effctor functions human IgG1 isotype controls are useful for in vivo use.

The isotype controls are normally used to differentiate any non-specific background signal from the specific antibody signal, including the immunogenicity if used in animals. Most in vivo functional grade human IgG antibodies are used in mice for in vivo studies. Besides the antibody Complementarity-Determining Regions (CDRs), two human or humanized variable regions including the one in the human or humanized IgG isotype control do not necessarily induce the same immune response in mice because in some cases, even one amino acid difference can make difference. Mouse variable regions can be used to show the potential immunogenicity induced by the human variable regions in the human or humanized IgG antibodies to test. Thus, in some cases, it is better to use the mouse variable region in the human IgG isotype controls. We also produce and sell recombinant human IgG isotype controls from the popuplar mouse hybridoma clones, MOPC21 and C1.18.4, as well as recombinant human IgG1 kappa isotype controls against KLH, TNP, DNP, GST, HEL, His-tag, DYKDDDDK, c-myc, HA, GFP, and unknown specificity.

Please contact us to ask for a quote for the Fc silenced human IgG1 isotype control mutants, hIgG1 isotype control and silent Fc mutants with Avi-, His-, and DYKDDDDK-tags, and biotinylated hIgG1 isotype control and Fc silent mutants. A variety of conjugates (such as a fluorophore) with the human IgG1 isotype control and Fc effector-silent mutants are available.

PA007125: In Vivo Grade Recombinant Human IgG1 kappa Isotype Control Antibody (hIgG1 Isotype Control)

The in vivo grade recombinant human IgG1 kappa isotype control antibody (hIgG1 isotype control) was produced in CHO cells.
Immunogen: N/A.
Clone: 4F17.
Isotype: human IgG1, kappa.
Applications: an isotype-matched negative control for human IgG1 kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method. Endotoxin ≤0.05 EU/mg for PA007125.05, in vivo grade recombinant human IgG1 isotype control antibody, premium grade (endotoxin ≤0.05 EU/mg).
RRID: AB_3717338.

PA007134: In Vivo Grade Recombinant Human IgG1-L234A L235A P329G (hIgG1 LALAPG) kappa Isotype Control Antibody (hIgG1 LALAPG Isotype Control)

The in vivo grade recombinant human IgG1-L234A L235A P329G (hIgG1 LALAPG, Fc silenced) kappa isotype control mutant (hIgG1 LALAPG isotype control) was produced in CHO cells.
Immunogen: N/A.
Clone: 4F17.
Isotype: human IgG1, kappa.
Applications: an isotype-matched negative control for human IgG1 LALAPG kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method. Endotoxin ≤0.05 EU/mg for PA007134.05, in vivo grade recombinant human IgG1-L234A L235A P329G (hIgG1 LALAPG) isotype control antibody, premium grade (endotoxin ≤0.05 EU/mg).

PA007133: In Vivo Grade Recombinant Human IgG1-N297A kappa Isotype Control Antibody (hIgG1 N297A Isotype Control)

The in vivo grade recombinant human IgG1-N297A kappa isotype control mutant (hIgG1 N297A isotype control) was produced in mammalian cells.
Immunogen: N/A.
Clone: 4F17.
Isotype: human IgG1, kappa.
Applications: an isotype-matched negative control for human IgG1 N297A kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007132: In Vivo Grade Recombinant Human IgG1-D265A kappa Isotype Control Antibody (hIgG1 D265A Isotype Control)

The in vivo grade recombinant human IgG1-D265A kappa isotype control mutant (hIgG1 D265A isotype control) was produced in mammalian cells.
Immunogen: N/A.
Clone: 4F17.
Isotype: human IgG1, kappa.
Applications: an isotype-matched negative control for human IgG1 D265A kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007139: In Vivo Grade Recombinant Human IgG1-D265A N297A kappa Isotype Control Antibody (hIgG1 DANA Isotype Control)

The in vivo grade recombinant human IgG1-D265A N297A (hIgG1 DANA) kappa isotype control mutant (hIgG1 DANA isotype control) was produced in mammalian cells.
Immunogen: N/A.
Clone: 4F17.
Isotype: human IgG1, kappa.
Applications: an isotype-matched negative control for human IgG1 DANA kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007140: In Vivo Grade Recombinant Human IgG1-S267E L328F (hIgG1 SELF) kappa Isotype Control Antibody (hIgG1 SELF Isotype Control)

The in vivo grade recombinant human IgG1-S267E L328F (hIgG1 SELF, Fc activated) kappa isotype control mutant (hIgG1 SELF isotype control) was produced in mammalian cells.
Immunogen: N/A.
Clone: 4F17.
Isotype: human IgG1, kappa.
Applications: an isotype-matched negative control for human IgG1 SELF kappa antibodies used in ELISA, Western Blot (WB), Flow Cytometry (Flow), Immunoprecipitation (IP), Immunohistochemistry (Paraffin) (IHC (P)), Immunohistochemistry (Frozen) (IHC (F)), and in vivo animal model research.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
12 months from date of receipt, -20°C to -70°C as supplied.

References of Human IgG1 Isotype Control Antibody

Dai Y, Knisely A, Yano M, et al. Nature. 2025;645(8082):E10. PMID: 40604275
"This study used Syd Labs in vivo grade recombinant human IgG1 isotype control (PA007125, 4 mg/kg, intraperitoneal injection, twice weekly for 3 weeks) as the isotype-matched negative control for anti-PD-L1 antibody therapy in humanized Hu-BLT mouse PDX models of endometrial cancer. Tumor weights were measured at endpoint to assess anti-PD-L1 therapeutic efficacy in PPP2R1A-mutant vs wild-type tumors, demonstrating that the recombinant human IgG1 isotype control showed no non-specific anti-tumor activity under in vivo dosing conditions suitable for humanized mouse oncology studies."
(Tags: human IgG1 isotype control in vivo; PDX model isotype control; anti-PD-L1 in vivo study; Cites Syd Labs PA007125; recombinant human IgG1 isotype control 4 mg/kg i.p.)
Maciuba S, Bowden GD, Stratton HJ, et al. mAbs. 2023;15(1):2254676. PMID: 37698877
"This study validated Syd Labs recombinant human IgG1 isotype control (PA007125), human IgG2 isotype control (PA007127), and human IgG4 isotype control (PA007128) as reference standards in Fc gamma receptor (FcγRI, FcγRIIA-H131, FcγRIIIA-V158, FcγRIIIA-F158) binding immunoassays. The human IgG1 isotype control showed expected FcγR binding profiles (IC50 of 0.33 nM for FcγRI and 5.9 nM for FcγRIIIA-V158, with no measurable binding to FcγRIIA-H131), confirming its utility as a wild-type human IgG1 benchmark in Fc effector function characterization of therapeutic antibodies."
(Tags: human IgG1 isotype control FcγR binding; recombinant hIgG1 isotype standard; Fc effector function assay; Cites Syd Labs PA007125; wild-type hIgG1 benchmark)
Huang X, Wang Q, Nan Y, Zhang X, Xu K, Ju D, Ding W. Biomedicines. 2024;12(9):2152. PMID: 39335665
"This study employed a recombinant human IgG1 isotype control antibody (2.4 mg/kg, intraperitoneal injection, twice weekly for 4 weeks) as the negative control group in HSPCs-CDX humanized mouse bladder cancer xenograft models. The isotype control group established baseline tumor growth and body weight parameters, against which combined anti-CD47 plus anti-angiogenesis therapy demonstrated significant tumor growth inhibition, confirming that the observed in vivo anti-tumor effect was antigen-specific and not attributable to non-specific Fc-mediated effects of the human IgG1 backbone."
(Tags: human IgG1 isotype control in vivo; bladder cancer CDX model; recombinant hIgG1 isotype 2.4 mg/kg; anti-CD47 in vivo; humanized mouse isotype control)
Sue M, Tsubaki T, Ishimoto Y, et al. PLoS One. 2024;19(6):e0304985. PMID: 38843278
"This study used an ultra-low endotoxin (ultra-LEAF) purified recombinant human IgG1 isotype control antibody as the isotype-matched negative control for a human IgG1 DXd antibody-drug conjugate (ADC) in in vivo solid tumor models. The recombinant human IgG1 isotype control confirmed that DXd-ADC combination with anti-SIRPα treatment produced enhanced anti-tumor activity not seen in isotype control groups, supporting the use of endotoxin-controlled recombinant human IgG1 isotype controls for in vivo ADC combination studies."
(Tags: recombinant human IgG1 isotype control in vivo; ultra-LEAF purified hIgG1; antibody-drug conjugate isotype control; anti-SIRPα CD47 in vivo; endotoxin-free isotype)
Cao Z, Wichmann CW, Burvenich IJG, et al. Eur J Nucl Med Mol Imaging. 2024;51(11):3202-3214. PMID: 38730087
"This study used a 89Zr-radiolabeled human IgG1 isotype control antibody co-injected with the anti-PD-L1/4-1BB bispecific antibody ATG-101 in BALB/c nude mice bearing MDA-MB-231 triple-negative breast cancer xenografts for immuno-PET imaging. The human IgG1 isotype control demonstrated minimal non-specific tumor accumulation in PD-L1-negative versus PD-L1-positive tumors, validating the targeting specificity of the PD-L1-directed bispecific antibody and establishing a reference for background signal quantification in in vivo imaging studies."
(Tags: human IgG1 isotype control in vivo; immuno-PET imaging isotype; PD-L1 bispecific antibody; MDA-MB-231 xenograft; tumor targeting specificity control)
Willoughby JE, Dou L, Bhattacharya S, et al. J Immunother Cancer. 2024;12(7):e008677. PMID: 38964788
"This study compared in vivo anti-tumor activity of anti-OX40 agonist antibodies formatted as human IgG1 versus other human isotypes in hOX40 knock-in mice bearing EG.7-OVA syngeneic tumors and in OT-I T cell adoptive transfer models. Human IgG1 isotype control antibodies confirmed that anti-OX40 efficacy depended on both antigen targeting and FcγR-mediated cross-linking in vivo, and that wild-type human IgG1 backbone provided the most favorable co-stimulatory agonist activity among the isotypes tested, supporting its use as the standard isotype backbone and control for therapeutic agonist antibodies."
(Tags: human IgG1 isotype control in vivo; agonist anti-OX40 antibody; FcγR cross-linking in vivo; hOX40 knock-in mouse; human IgG1 therapeutic isotype backbone)
Trilleaud C, et al. Sci Adv. 2021;7(14):eabd1453. PMID: 33811066
"This study used a human IgG1 isotype control antibody in both acute DSS-induced colitis and chronic TNBS-induced colitis mouse models to evaluate the anti-inflammatory efficacy of an agonist anti-ChemR23 monoclonal antibody. The human IgG1 isotype control groups showed baseline neutrophil accumulation and tissue inflammation levels, against which the anti-ChemR23 antibody demonstrated significant reduction of tissue neutrophil infiltration and accelerated resolution of chronic intestinal inflammation, confirming that the observed therapeutic effect was target-specific and not mediated by the human IgG1 Fc backbone."
(Tags: human IgG1 isotype control in vivo; colitis model isotype; neutrophil inflammation resolution; anti-ChemR23 agonist antibody; DSS TNBS colitis)
Daniels-Wells TR, Candelaria PV, Leoh LS, Nava M, Martínez-Maza O, Penichet ML. J Immunother. 2020;43(2):48-52. PMID: 31693515
"This study used a human IgG1 isotype control antibody as the negative control in disseminated multiple myeloma xenograft models (KMS-11, MM.1S, MM.1R) in SCID-Beige mice to assess the anti-tumor activity of an anti-TfR1 human IgG1 antibody (ch128.1IgG1). The human IgG1 isotype control groups developed disseminated disease and hind-limb paralysis as expected, while ch128.1IgG1 treatment significantly prolonged survival, demonstrating that the observed in vivo anti-myeloma activity was antigen-specific and dependent on Fc-mediated effector functions rather than non-specific human IgG1 effects."
(Tags: human IgG1 isotype control in vivo; multiple myeloma xenograft; SCID-Beige mouse model; anti-TfR1 antibody Fc-mediated; disseminated disease survival study)
For more technical references or data sheets regarding the Recombinant Human IgG1 Isotype Control Antibody formats, please contact our scientific support team at message@sydlabs.com.

The following mutations have been introduced to alter the constant regions of an IgG1 antibody to change its immunologic properties by Fc interaction with host proteins:

hIgG1 heavy chain R214K
hIgG1 heavy chain R214K/N297A
hIgG1 heavy chain L234A/L235A
hIgG1 heavy chain L234F/L235E/P331S
hIgG1 heavy chain L235A/G237A
hIgG1 heavy chain D356E/L358M
hIgG1 heavy chain F126L
hIgG1 heavy chain D265A
hIgG1 heavy chain F243L/R292P/Y300L/V305I/P396L
hIgG1 heavy chain S239D/I332E
hIgG1 heavy chain S239D/I332E/A330L
hIgG1 heavy chain S298A/E333A/K334A
hIgG1 heavy chain G236A/S239D/I332E
hIgG1 heavy chain K326W/E333S
hIgG1 heavy chain S267E/H268F/S324T
hIgG1 heavy chain E345R/E430G/S440Y
hIgG1 heavy chain N297A
hIgG1 heavy chain N297Q
hIgG1 heavy chain N297G
hIgG1 heavy chain L235E
hIgG1 heavy chain L234A/L235A
hIgG1 heavy chain M252Y/S254T/T256E
hIgG1 heavy chain M428L/N434S
hIgG1 heavy chain S267E/L328F
hIgG1 heavy chain N325S/L328F

Other in vivo grade Recombinant IgG Isotype Control Antibodies and Mutants:
In vivo Grade Recombinant Human IgG1 Isotype Control Antibody and Mutants
In vivo Grade Recombinant Human IgG2 Isotype Control Antibody
In vivo Grade Recombinant Human IgG3 Isotype Control Antibody
In vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2b Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG3 Isotype Control Antibody
In vivo Grade Recombinant Rat IgG1 Isotype Control Antibody
In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody
In vivo Grade Recombinant Rat IgG2b Isotype Control Antibody
In vivo Grade Recombinant Rat IgG2c Isotype Control Antibody
In vivo Grade Recombinant Hamster IgG1 Isotype Control Antibody
In vivo Grade Recombinant Hamster IgG2 Isotype Control Antibody

In vivo Grade Recombinant IgG Fc Proteins:
In vivo Grade Recombinant Human IgG1 Fc Protein (hIgG1)
In vivo Grade Recombinant Human IgG2 Fc Protein (hIgG2)
In vivo Grade Recombinant Human IgG4 Fc Protein (hIgG4)
In vivo Grade Recombinant Mouse IgG1 Fc Protein (mIgG1)
In vivo Grade Recombinant Mouse IgG2a Fc Protein (mIgG2a)
In vivo Grade Recombinant Mouse IgG2b Fc Protein (mIgG2b)
In vivo Grade Recombinant Rat IgG2a Fc Protein (rtIgG2a)
In vivo Grade Recombinant Rat IgG2b Fc Protein (rtIgG2b)
In vivo Grade Recombinant Llama IgG2b Fc Protein (lIgG2b)
In vivo Grade Recombinant Rabbit IgG Fc Protein (rIgG)

Fc ELISA Kits and Reagents:
Human Fc ELISA Kit
Mouse Fc ELISA Kit
Human Fc ELISA Reagent Kit
Mouse Fc ELISA Reagent Kit

Protein A, Resin, Columns, and ELISA Kits:
Recombinant Protein A
Protein A Affinity Resin
Pre-packed Protein A Column
Protein A ELISA Kit

Related Links

See our Privacy Policy